Svoboda | Graniru | BBC Russia | Golosameriki | Facebook

Progress Toward Polio Eradication - Worldwide, January 2019-June 2021

MMWR Morb Mortal Wkly Rep. 2021 Aug 27;70(34):1129-1135. doi: 10.15585/mmwr.mm7034a1.

Abstract

In 1988, when the Global Polio Eradication Initiative (GPEI) began, polio paralyzed >350,000 children across 125 countries. Today, only one of three wild poliovirus serotypes, type 1 (WPV1), remains in circulation in only two countries, Afghanistan and Pakistan. This report summarizes progress toward global polio eradication during January 1, 2019-June 30, 2021 and updates previous reports (1,2). In 2020, 140 cases of WPV1 were reported, including 56 in Afghanistan (a 93% increase from 29 cases in 2019) and 84 in Pakistan (a 43% decrease from 147 cases in 2019). As GPEI focuses on the last endemic WPV reservoirs, poliomyelitis outbreaks caused by circulating vaccine-derived poliovirus (cVDPV) have emerged as a result of attenuated oral poliovirus vaccine (OPV) virus regaining neurovirulence after prolonged circulation in underimmunized populations (3). In 2020, 32 countries reported cVDPV outbreaks (four type 1 [cVDPV1], 26 type 2 [cVDPV2] and two with outbreaks of both); 13 of these countries reported new outbreaks. The updated GPEI Polio Eradication Strategy 2022-2026 (4) includes expanded use of the type 2 novel oral poliovirus vaccine (nOPV2) to avoid new emergences of cVDPV2 during outbreak responses (3). The new strategy deploys other tactics, such as increased national accountability, and focused investments for overcoming the remaining barriers to eradication, including program disruptions and setbacks caused by the COVID-19 pandemic.

MeSH terms

  • Disease Eradication*
  • Disease Outbreaks / statistics & numerical data
  • Endemic Diseases / statistics & numerical data
  • Global Health / statistics & numerical data*
  • Humans
  • Immunization Programs
  • Poliomyelitis / epidemiology
  • Poliomyelitis / prevention & control*
  • Poliovirus Vaccines / administration & dosage
  • Population Surveillance*

Substances

  • Poliovirus Vaccines